James B. Hawkins - Dec 7, 2021 Form 4 Insider Report for IRADIMED CORP (IRMD)

Role
Director
Signature
/s/ James Hawkins
Stock symbol
IRMD
Transactions as of
Dec 7, 2021
Transactions value $
-$880,834
Form type
4
Date filed
12/9/2021, 08:40 PM
Previous filing
Nov 30, 2021
Next filing
Feb 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRMD Common Stock Award $27.7K +18.7K +108.54% $1.48 36K Dec 7, 2021 Direct F1
transaction IRMD Common Stock Sale -$882K -18.7K -52.05% $47.07 17.3K Dec 7, 2021 Direct F2
transaction IRMD Common Stock Options Exercise +4.22K +24.45% 21.5K Dec 7, 2021 Direct F3
transaction IRMD Common Stock Award $827 +559 +2.6% $1.48 22K Dec 8, 2021 Direct F1
transaction IRMD Common Stock Sale -$27.1K -559 -2.54% $48.50 21.5K Dec 8, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IRMD Stock Options (Right to Buy) Options Exercise $0 -18.7K -65.21% $0.00 10K Dec 7, 2021 Common Stock 18.7K $1.48 Direct F1
transaction IRMD Restricted Stock Units Options Exercise $0 -4.22K -67.45% $0.00 2.04K Dec 7, 2021 Common Stock 4.22K Direct F3, F4
transaction IRMD Restricted Stock Units Award $0 +2.07K $0.00 2.07K Dec 7, 2021 Common Stock 2.07K Direct F4, F5
transaction IRMD Stock Options (Right to Buy) Options Exercise $0 -559 -5.59% $0.00 9.44K Dec 8, 2021 Common Stock 559 $1.48 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option, representing a right to purchase a total of 140,000 shares, was granted on 12-31-2013 and vested over 4 years in equal annual installments commencing on the first anniversary of the grant date.
F2 This transaction was executed in multiple trades at prices ranging from $46.30 to $48.54. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2020 and 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.
F4 Restricted Stock Units convert to common stock on a one-for-one basis.
F5 The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2022. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.